Semliki Forest virus vectors for gene therapy.
Semliki Forest virus (SFV) vectors transduce a broad range of mammalian and non-mammalian cells, generating high levels of transient expression of heterologous proteins. Generally, they induce apoptosis in mammalian host cells, leading to rapid cell death. These features have made SFV attractive for various gene therapy applications. Recombinant particles, naked RNA and plasmid DNA containing SFV replicons, demonstrate a strong immune response against recombinantly expressed proteins, which has shown protection against tumour challenges. Intratumoural injection of SFV particles has resulted in tumour regression. SFV vectors have been used for production of retrovirus-like particles. Recently, encapsulation of SFV particles into liposomes has generated highly efficient targeting to tumours. Novel SFV vectors based on point mutations in the non-structural genes, and avirulent SFV strains, have further widened the application range.
Lundstrom
Kenneth
K
Regulon Inc./BioXtal, Chemin des Croisettes 22, CH-1066 Epalinges, Switzerland. Kenneth.Lundstrom@mepnet.org
D000818:Animals; D018390:Gene Targeting; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D006801:Humans; D007114:Immunization; D009369:Neoplasms / Q000628:therapy; D012190:Retroviridae / Q000235:genetics; D012672:Semliki forest virus / Q000235:genetics*; D019444:Vaccines, DNA / Q000008:administration & dosage
D019444:Vaccines, DNA